Talquetamab + teclistamab in patients with triple-class exposed R/R MM and EMD: The RedirecTT-1 study Talquetamab + teclistamab in patients with triple-class exposed R/R MM and EMD: The RedirecTT-1 study June 2025 Congress News Read more
2023 October ASCO 2023 Obe-cel yields high remission rates in relapsed/refractory B-ALL patients Read more
2023 October Clinical trials Continued support for daratumumab plus pomalidomide and dexamethasone in myeloma Read more
2023 October Clinical trials Belantamab mafodotin fails to delay disease progression in R/R multiple myeloma Read more
2023 September Medical Research Maternal haemoglobin concentrations and their impact on maternal and neonatal outcomes Read more
2023 September Clinical trials Axi-cel as an effective second-line treatment for R/R LBCL patients ineligible for transplanta... Read more
2023 September Pharma News FDA grants accelerated approval to elranatamab for the treatment of R/R multiple myeloma Read more
Top
